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RadiotherapyAbstract The objective of this study was to compare the diagnostic accuracy of transvaginal ultra-
sound (TVS), as a less invasive technique instead of hormonal assay to evaluate the ovarian reserve.
This study included ﬁfty-ﬁve females with breast cancer and we compared the ovarian reserve for
these patients by hormonal assay through measuring the serum AntiMullerian Hormone (AMH)
level and follicular stimulating hormone (FSH) level before and after chemotherapy, and by
transvaginal ultrasound through the ovarian volume (OV) calculation and counting the Antral fol-
licles (AFC) before and after chemotherapy treatment. There was decline in the AntiMullerian Hor-
mone level after chemotherapy by 27 ± 11.19% and decrease in the Antral follicle counts by 21 ±
13.43%. In conclusion there was strong relation between AMH level and AFC which makes the use
of transvaginal ultrasound is a reliable alternative method to the hormonal assay to detect the
ovarian reserve.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Ovarian reserve tests (ORT) play important parts in detecting
and treating infertility. They also play important parts in eval-
uation of women prior to in vitro fertilization (1). ORT has to
be easy to perform, easy to be followed up and reliable enough
for decision making (2). Many situations as old patients, or
chronic illness patients seeking for pregnancy and preparation
of woman to IVF are in need for accurate method to detect the
response to treatment (3), also up to one third of the cancer
survivals, undergo the fertility testing, place them into the cat-egory of suspected infertility, compared with an infertility rate
of around 5% in the corresponding age segment of the general
population. Ovarian aging, radiotherapy and chemotherapy
are the most common causes for fertility loss in women. With
increasing numbers of young female survivors following cyto-
toxic cancer treatments, the issue of fertility preservation has
assumed greater importance (4).
1.1. Aim of the work
The objective of this study was to assess the ability of ultra-
sound in evaluating ovarian reserve, and whether we can use
ultrasound instead of hormones in decision making regarding
ovulation induction and IVF.
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This study was done at National center of radiation and
research technology and Al-Zahraa University Hospital from
September 2014 to January 2015.
Fifty-ﬁve females were subjected to treatments of breast
cancer that include surgery, radiotherapy and chemotherapy
are used to measure ovarian reserve before and after treat-
ment. Serum Anti-Mu¨llerian hormone (AMH) and Follicular
stimulating hormone (FSH) were measured before and after
treatment, and used as a reference for the fertility. Antral fol-
licle count (AFC) and ovarian volume (OV) were measured
before and after treatment by ultrasonography for all patients
and compared with the hormonal assay to detect the reliability
of this modality.
2.1. Technique of imaging
All patients undergo GE machine Logic P6 pro and My
LabTM50 – Esaote.
Transvaginal sonography that was described about two
decades ago is more precise because it provides better resolu-
tion and hence more morphological details of the ovaries 5.
The patient was in the supine position using the vaginal probe
for better detection of Antral follicles and determination of
ovarian volume 6. The scan starts by viewing the uterus both
longitudinal and cross-sectional and measuring the endome-
trium, after that both ovaries both longitudinal and cross-
sectional (Fig. 1) are scanned to assess volume and the Antral
follicles are counted ranging from 3 to 10 mm. Then, blood
sample was taken and used to detect the level of Anti-
Mullerian Hormone (AMH) and follicle stimulating hormone
(FSH). The AMH level was analyzed by the competitive
enzyme immunoassay technique, and the FSH by Enzyme-
Linked Immuno Sorbent Assay (ELISA) (see Fig. 2).Fig. 1 Transvaginal examination sh2.2. Statistical analysis
Data were analyzed using Statistical Package for Social
Science (SPSS) version 21.0. Quantitative data were expressed
as mean and standard deviation (SD). Paired-samples t-test of
signiﬁcance was used for calculating the mean differences
between measurements of the three hormones and ovarian vol-
ume size before and after treatment. P-value <0.05 was con-
sidered signiﬁcant and P-value <0.01 was considered highly
signiﬁcant. Conﬁdence intervals were calculated with the soft-
ware Conﬁdence Interval Analysis (CIA) for windows, devel-
oped using Borland Delphi v 4.0 (Inprise Corporation) and
ForHelp (ForeFront Technologies.)
3. Results
This study was conducted to evaluate whether ultrasound is
an effective modality to measure ovarian reserve by measur-
ing Antral follicle count and ovarian volume of patients who
are subjected to cancer treatment. This study contains 55
patients with mean age of 32.5 and standard deviation of
4.9 ranging from 22 to 40 years. Statistical analysis of the
measurements before and after treatment is shown in Table 1.
The mean differences in measurements before and after treat-
ment with their conﬁdence intervals are shown in Table 2, the
p values were all below 0.0001 indicating a high signiﬁcant
difference in the measurements before and after treatment
in the 4 items measured. The negative sign in the FSH values
is due to the increase in measurements after treatment in con-
trary to the other three items which show drop in measure-
ments. Statistical analysis of the percentage of changes in
measurements before and after treatment is described in
Table 3. The median, range and the quartiles values of the
percentage change of AMH, AFC, OV and FSH are shown
in Figs. 3–6 respectively.owing ovarian volume technique.
Fig. 2 Transvaginal US showing Antral follicle counts and ovarian volume.
Table 1 Descriptive analysis of the measurements before and after treatment.
Mean N Std. deviation Std. error mean
Pair 1 AMH before 3.4600 55 .73273 .09880
AMH after 2.4982 55 .63377 .08546
Pair 2 FSH before 21.0000 55 7.21375 .97270
FSH after 31.0873 55 8.26044 1.11384
Pair 3 AFC before 6.9455 55 1.90922 .25744
AFC after 5.3273 55 1.24803 .16828
Pair 4 Ovarian volume before 6.0309 55 2.42501 .32699
Ovarian volume after 4.7891 55 1.79719 .24233
Table 2 Mean differences between measurements before and after treatment.
Paired diﬀerences T P value < 0.0001 in all
Mean Std. deviation Std. error mean 95% Conﬁdence interval of the
diﬀerence
Lower Upper
AMH before – AMH after 0.96182 0.48819 0.06583 0.82984 1.09379 14.611
FSH before – FSH after 10.08727 5.2333 0.70566 11.50203 8.67251 14.295
AFC before – AFC after 1.61818 1.14651 0.15459 1.30824 1.92813 10.467
OV before – OV after 1.24182 1.20226 0.16211 0.9168 1.56684 7.66
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Ovarian reserve is very crucial part in predicting assisted
reproductive treatment, a combination of clinical endocrinal
and ultrasonic measures is used for this (5), and our study
was designed to see whether or not ultrasound can replace
the endocrinal ways in follow-up. In our study there wasmarked decrease in ovarian reserve reﬂected on both hormonal
and ultrasonic measurements, this goes with who reported
decrease in ovarian Antral follicle count after cancer therapies
(6,7). Cancer itself can impair ovarian reserve. Hormone and
ultrasound measures of ovarian reserve suggest decreased
underlying ovarian reserve comparing before and after therapy
(8). So we used this decline in function to measure the
Table 3 Mean percentage changes in measurements before
and after treatment.
Percentage of
change in
measurements
before and
after treatment
Paired diﬀerences
Mean Std.
deviation
Std.
error
mean
95% Conﬁdence
interval of the
diﬀerence
Lower Upper
AMH 27.3739 11.1914 1.50905 24.3485 30.3994
FSH 55.2227 35.6944 4.81304 45.5732 64.8723
AFC 21.3848 13.4395 1.81218 17.7516 25.018
OV 18.7308 12.0968 1.63113 15.4606 22.001
Fig. 4 Percentage of decrease in AFC with a mean of 21.38%.
Fig. 5 Percentage of decrease in OV with a mean of 18.73%.
1346 E.A.S. Sabek et al.percentage of change and whether this decline reﬂected on
ultrasound parameter as well as hormones in the same
percentage.
Anti-Mu¨llerian Hormone (AMH) is a very sensitive indica-
tor of the ovarian follicular content. Mu¨llerian hormone is the
most informative serum marker of ovarian reserve currently
available and should be considered an important part of any
contemporary reproductive medicine practice. It is more con-
venient and informative than basal FSH and can be assessed
at any point in the cycle. It is the most useful serum method
of determining ovarian reserve, which guides pretreatment
counseling, choice of infertility treatment, and avoidance of
ovarian hyperstimulation (9).
So we started by comparing both AFC and OV with the
AMH. In our study there is a strong relation between AFC
and AMH as both of them show decrease after cancer therapy,
the former by 27 ± 11.19% and AFC by 21 ± 13.43%. This
goes with Fanchin et al. (10) who correlated between AFC
and the level of AMH as the AMH shown to be produced
by the Antral follicle. Lan et al. (11) assess the use of AFC
and AMH in the treatment of infertility, both of them shown
to have the same predictive value regarding ovarian reserve.
Verhagen et al. (12) stated that AFC is as accurate as the
multivariate model and there are no beneﬁts of using variousFig. 3 Percentage of decrease in AMH with a mean of 27.37%.models over using AFC alone. Bansci et al. showed that
AFC as a single variable was the best predictor of poor
response with sensitivity and speciﬁcity of 62% and 88%
respectively (9,13). Transvaginal ultrasound estimation of
Antral follicle counts (AFCs) is a useful indicator of ovarian
function and reserve (14).
Some authors such as Mutiu et al. (15) show that AFC
determines poor ovarian response more than AMH. Various
studies mentioned the proper size of Antral follicle, Mutiu
et al. (15) used a range from 2 to 10 mm, and in our study
we used Antral follicle ranging from 3 to 10 mm. Others such
as Jayaprakasan et al. (5) mention the 2–6 mm is the proper
size who also stated that there is no any correlation between
hormonal markers and AFC. As the ultrasonography is oper-
ator dependent manufacturer made a software for easier auto-
matic analysis of Antral follicle, in this software each follicle is
given a special color, also these follicles are subdivided into
cohorts according to their mean diameter calculated automat-
ically into groups according to size by sono AFC. Manual
Fig. 6 Percentage of increase in FSH with a mean of 55.22%.
Fig. 7 The software individually color codes each identiﬁed follicle
follicles with its mean and absolute diameters and its volume 7.
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them for more accuracy (Fig. 7) (5).
Ovarian volume increases exponentially from birth to
pubertal ages and are believed tope at a maximum shortly
after puberty (16). It can be measured by using the formula
(D1  D2  D3  0.523), and the mean volume is the aver-
age of the two ovaries in the same person (17). Ovarian vol-
ume is important for accurate evaluation and management of
ovarian disorders (18). Some authors questioned the role of
ovarian volume in the assessment of ovarian reserve and
showed that it remains uncertain, with some studies suggest-
ing that a reduced volume is a good predictor of poor out-
come for assisted conception (19,20). Several studies showed
that low ovarian volume <3 ml is predictor for poor
response to ovarian stimulation (21). In this study ovarian
volume decreased by 18.7 ± 12.09% from the former ovarian
volume. It was the least one to be affected but is very close to
AFC and AMH, ovaries with nonfunctional cysts are fol-
lowed up until disappearance of the cyst so as to avoid false
increase in size, and modern machines using 3-D techniqueand provides an objective measurement of the number of Antral
1348 E.A.S. Sabek et al.reduce inter-observer variability but this needs specialized
equipment.
Basal FSH level increases at day 2–3–4 of the cycle it also
has signiﬁcant intra-cycle and inter-cycle variability that limits
their reliability, and also the absolute value can differ from one
to another. But the overall correlation between values is shown
to have signiﬁcance (22). Despite this limitation FSH com-
monly used as a measurement for ovarian reserve and high
value are associated with poor ovarian stimulation and inabil-
ity to conceive. In our study there was high signiﬁcant increase
in serum level of FSH with the mean value reaching 55.2%
after treatment which put them in postmenopausal level. These
results corroborate ﬁndings of study by Gracia et al. (2012),
who reported increased FSH levels in patients after cancer
therapy. The future role of basal FSH testing is in doubt (9).
There is evidence that Anti-Mu¨llerian Hormone (AMH) and
follicular stimulating hormone (FSH) levels may correlate well
with Antral follicle counts and may be more consistent mark-
ers of ovarian reserve (23).
The use of wide range of tests suggests that no single test
provides a sufﬁciently accurate result. But the simultaneous
evaluation of a combination of tests could be used as a marker
of diminished ovarian reserve and a sensitive predictor of
response to ovarian stimulation in patients undergoing
in vitro fertilization treatment (24). In our study there is evi-
dence that Anti-Mu¨llerian Hormone (AMH), Antral follicle
count (AFC) and ovarian volume (OV) levels correlate well
with each other more consistent markers of ovarian reserve.
Regarding FSH there was marked increase reaching up to
55.2% which was more than the percentage of decrease of
other markers.
5. Conclusion
The use of ultrasound in detecting ovarian reserve by detection
of Antral follicle counts is very easy, minimal invasive, inex-
pensive and has good predictive value. It can be used instead
of hormones on the basis of follow-up to detect either increase
or decrease of ovarian function.
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